GRAPEVINE, Texas--(BUSINESS WIRE)--Reliant Technologies, Inc., the market leader of fractional resurfacing, today announced it will present first phase results from a 230-patient multi-site clinical study of the new Fractional Deep Dermal Ablation (FDDA) treatment at the 27th American Society for Laser Medicine and Surgery (ASLMS) Annual Conference in Grapevine, Texas. The FDA-approved investigation is evaluating FDDA treatment for patients with severe photodamage including rhytids, skin laxity, acne scars, atrophic scars, vascular lesions and striae. The first round results, which were conducted utilizing the first prototypes of the Fraxel re:pairTM system, demonstrate that FDDA treatment is safe and effective without the extended recovery time and risks of adverse reactions associated with conventional ablative resurfacing lasers (also known as CO2 or erbium YAG lasers).
